US Stock Insider Trading | Johnson & Johnson disclosed 65 insider transactions on February 18

K-LinePoet · 2026-02-20T18:44:50+00:00

On February 18, 2026, Johnson & Johnson disclosed insider trading activities of executives and directors. Executive Wolk Joseph J bought 33,400 shares on February 18, and director Duato Joaquin sold 32,700 shares on February 13, for a total of $7,989,000. Johnson & Johnson focuses on the research, development, and sales of healthcare products.

K-LinePoet

2026-02-20 18:44:50

Abstract generation in progress

On February 18, 2026, Johnson & Johnson (JNJ) disclosed 65 insider trading transactions. Executive Wolk Joseph J purchased 33,400 shares on February 18, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 18, 2026	Executive	Wengel Kathryn E	February 15, 2026	Sell	635	243.45	154,600
February 18, 2026	Executive	Wengel Kathryn E	February 13, 2026	Sell	6,631	244.55	1,621,600
February 18, 2026	Executive	Mulholland Kristen	February 13, 2026	Sell	1,162	244.55	284,200
February 18, 2026	Executive	Mulholland Kristen	February 15, 2026	Sell	423	243.45	102,900
February 18, 2026	Executive	Forminard Elizabeth	February 13, 2026	Sell	7,325	244.55	17,913,000
February 18, 2026	Executive	Forminard Elizabeth	February 15, 2026	Sell	1,036	243.45	25,200
February 18, 2026	Director	Duato Joaquin	February 15, 2026	Sell	3,562	243.45	8,672,000
February 18, 2026	Director	Duato Joaquin	February 13, 2026	Sell	32,700	244.55	7,989,000
February 18, 2026	Executive	Swanson James D.	February 17, 2026	Buy	20,500	164.62	3,378,200
February 18, 2026	Executive	Swanson James D.	February 13, 2026	Buy	22,200	162.75	3,611,600

[Company Profile]

Johnson & Johnson was founded in 1887 in New Jersey and is a leading global healthcare company. The company focuses on researching, developing, manufacturing, and selling a wide range of healthcare products, emphasizing human health and well-being. Johnson & Johnson operates through two main business segments: innovative pharmaceuticals and medical devices.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes